Patiromer (Veltassa®)

Assessment Status Awaiting re-submission of HTA from Applicant
Drug Patiromer
Brand Veltassa®
Indication For the treatment of hyperkalaemia in adults.
Assessment Process
Rapid review commissioned 11/10/2017
Rapid review completed 17/11/2017
Rapid review outcome Full Pharmacoeconomic Assessment Recommended
Full pharmacoeconomic assessment commissioned by HSE 20/11/2017
Pre-submission consultation with Applicant 16/01/2018
Full submission received from Applicant 13/04/2018
Preliminary review sent to Applicant 15/10/2018
NCPE assessment re-commenced 13/11/2018
Factual accuracy sent to applicant 21/01/2019
NCPE assessment re-commenced 04/02/2019
NCPE assessment completed 13/02/2019
NCPE assessment outcome The NCPE recommends that patiromer (Veltassa®) not be considered for reimbursement*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

Technical Summary

Re-submission of HTA

NCPE Assessment Process
Re-submission of HTA commissioned by the HSE 30/06/2020
Pre-submission consultation with Applicant 23/11/2020
Current status Awaiting HTA submission from Applicant